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WHAT THIS PAPER ADDS
 In this study, although underpowered for deﬁnite conclusions, high-dose vitamin D substitution did not alter parameters of arterial
stiffness, microcirculation, inﬂammation and haemostasis in patients with peripheral arterial disease, adding more data to other
studies that did not conﬁrm a causal role of vitamin D in cardiovascular disease. Another result is a striking difference in the
individual response of serum vitamin D levels after a single, oral supplementation.a r t i c l e i n f o
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Objective: Apart from its role in bone metabolism, vitamin D may also inﬂuence cardiovascular disease.
The objective of this study was: (1) to determine the effect of a single, oral, high-dose vitamin D
supplementation on endothelial function and arterial stiffness in patients with peripheral arterial disease
(PAD) and (2) to investigate the impact of this supplementation on coagulation and inﬂammation
parameters.
Methods: In this double-blind, placebo-controlled, interventional pilot study, we screened 76 Caucasian
patients with PAD for vitamin D deﬁciency. Sixty-two were randomised to receive a single, oral
supplementation of 100 000 IU vitamin D3 or placebo. At baseline and after 1 month, we measured
serum vitamin D and parathormone levels, and surrogate parameters for cardiovascular disease.
Results: Sixty-ﬁve of 76 patients (86%) had low 25-hydroxyvitamin D levels (<30 ng ml1); of those, 62
agreed to participate in the study. At baseline, only parathormone was related to vitamin D. In supple-
mented patients, vitamin D levels increased from 16.3  6.7 to 24.3  6.2 ng ml1 (P < 0.001), with wide
variations between single patients; in the placebo group vitamin levels did not change. Seasonal factors
accounted for a decrease of vitamin D levels by 8 ng ml1 between summer and winter. After 1 month,
none of the measured parameters was inﬂuenced by vitamin substitution.
Conclusion: In this pilot study, most patients with PAD were vitamin D deﬁcient. Vitamin D supple-
mentation increased serum 25-hydroxyvitamin D without inﬂuencing endothelial function, arterial
stiffness, coagulation and inﬂammation parameters, although the study was underpowered for deﬁnite
conclusions.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Peripheral arterial disease (PAD), a clinical manifestation of
atherosclerosis, is associated with a high risk of morbidity and: þ41 91 811 47 83.
ciety for Vascular Surgery. Publishemortality from cardiovascular disease.1 The development and
progression of PAD is mediated by pathophysiological mechanisms
involving atherogenesis and thrombogenesis, leading to endothe-
lial damage and dysfunction, increased arterial stiffness and acute
thrombotic complications.2 Traditional risk factors for PAD, simi-
larly to other manifestations of atherosclerosis, include diabetesd by Elsevier Ltd. All rights reserved.
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parameters such as C-reactive protein (CRP) and homocysteine
were shown to be associated with PAD.4,5
Apart from its well-known role in bone and calcium metabo-
lism, vitamin D deﬁciency has recently received widespread
attention for its potential role as a risk factor in cardiovascular
disease6 and for its association with traditional cardiovascular risk
factors.7 Particularly, low serum 25-hydroxyvitamin D (25-OH
vitamin D) levels were associated with a higher prevalence of PAD.8
The serum 25-OH vitamin D concentration is accepted as the
nutritional parameter of vitamin D status, but controversy exists
about the deﬁnition of vitamin D deﬁciency. A recent recommen-
dation deﬁned the optimal vitamin D concentration to prevent
osteoporosis to be at least 30 ng ml1.9
In contrast with the positive results from cross-sectional or
observational studies, data from randomised controlled trials are
limited and conﬂicting10,11 or did not show an association of low
vitamin D levels with cardiovascular mortality.12 In a recent
statement, therefore, it was felt that the evidence for vitamin D
to reduce the risk of extra skeletal disease was as yet
inconsistent.13
We performed a randomised, double-blind, placebo-controlled
interventional pilot study in patients with PAD and vitamin D
deﬁciency with the objective to determine the effect of a single,
oral, high-dose vitamin D supplementation on surrogate markers
of endothelial function and arterial stiffness, known to correlate
with cardiovascular outcome14 and to investigate the impact of
this supplementation on coagulation and inﬂammation
parameters.
Materials and Methods
Subjects
The study was conducted at the regional hospital of Locarno
between May 2010 and February 2011. The protocol was approved
by the local Ethics Committee. Caucasian patients with chronic PAD
(deﬁned as an ankleebrachial index <0.9 plus a duplex or angio-
graphically based veriﬁcation of a >50% stenosis or occlusion in
a leg artery) were screened for vitamin D deﬁciency. Inclusion
criteria were: (1) a serum 25-hydroxyvitamin D level <30 ng ml1,
(2) unchanged medication in the 6 weeks prior to the study, (3) no
vascular interventions in the 2 months preceding the study and (4)
informed written consent. Exclusion criteria were: (1) acute inter-
current illness, (2) chronic critical ischaemia, (3) thromboangiitis
obliterans, (4) renal insufﬁciency deﬁned as serum creatinine
>130 mmol l1, (5) acute myocardial infarction or stroke within 2
months, (6) current oral anticoagulation medication, (7) liver
cirrhosis and (8) presence of an active malignant tumour.
Furthermore, patients were excluded if their medication was
changed during the study period.
At baseline and at the end of the study after 1 month, clinical
examination, blood collection and speciﬁc tests (see below) were
performed in all patients. All participants were instructed not to
expose themselves to sunlight during the study month. The study
had a double-blinded, randomised, parallel group design. After
randomisation in blocks of four (http://www.randomization.com),
half of the patients were given a vial containing 100 000 IU of
a single dose of an oily solution of vitamin D3 (cholecalciferol), thus
ensuring 100% compliance, the other half placebo (triglyceride and
ethylis gallas), both provided by Streuli Pharma AG (Uznach,
Switzerland). The vials were stored in the hospital’s pharmacy;
patients were allocated by the pharmacist to vitamin D or placebo
following the randomisation list, which was concealed to physician
and patient.Haemodynamic measurements
Endothelial functionwas assessed bymeasuring skin blood ﬂow
after ischaemic challenge using a laser Doppler ﬂowmeter (PF 3,
Perimed AB, Sweden), according to the method of Binggeli et al.15
Fasting patients were examined between 8:30 a.m. and 9:30 a.m.
in a room with constant ambient temperature, after a 15-min
resting period in a supine position. Reactive hyperaemia in skin
microcirculation has been validated as a measure related to other
established methods of endothelial function testing.15 Baseline
blood ﬂow measured as arbitrary units of laser Doppler ﬂux (LDF)
was registered for 5min using a probe ﬁxed by a probe-holder close
to the wrist. After 5 min, a cuff placed around the arm was left
inﬂated for 4.5 min. After release of the cuff, reactive hyperaemic
blood ﬂow was registered, and the difference of blood ﬂow
between baseline and the mean ﬂow between 30 and 60 s after
release was registered.
Central blood pressure using radial artery applanation tonom-
etry and sphygmocardiography (SphygmocCor version 7.1, AtCor,
Sydney, Australia) was measured according to the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT) protocol, by using
a validated, semiautomatic oscillometric device (Omron 705CP,
Omron, Amsterdam, the Netherlands) for brachial blood pressure.
After a 5-min rest, blood pressure over the brachial artery was
measured 3 times at 5-min intervals in seated patients, using the
mean of the last two measures. Hence, radial artery pressure
waveforms of the same arm were recorded over 10 s with a Millar
tonometer (SPC-301, Millar Instruments, Houston, TX, USA), and
waveforms were processed with the SygmoCor software to obtain
the corresponding central aortic-pressure waveform. From the
parameters provided by the software, augmentation index,
a parameter of arterial stiffness (AIx; the ratio of augmentation to
central pulse pressure, which is considered a marker of arterial
stiffening),14 corrected for heart rate, was obtained. The mean of at
least two consecutive radial pressurewave samplings were used for
calculating central pressure.
Laboratory analysis
At baseline and at the end of the study, bloodwas drawn from an
antecubital vein between 8 a.m. and 9 a.m. after 15 min of rest in
a supine position. Blood was collected in a 10-ml plastic syringe
(Monovette, Sarstedt, Nümbrecht, Germany) containing 1 ml
0.106 M trisodium citrate. Blood samples were immediately placed
on melting ice. Plasma was separated by cold centrifugation, and
aliquots were stored at 70 C until processing.
F1þ2 (Enzygnost F1þ2; Dade Behring, Marburg, Germany),
thrombineantithrombin complex (TAT) (Enzygnost TAT micro,
Dade Behring), D-dimer (miniVidas by bioMérieux, Lyon, France),
plasminogen activator inhibitor-1 (PAI-1) (Biopool, Umea, Sweden)
and Soluble CD40L (sCD40L) (Biosource, Camarillo, CA, USA) were
determined by enzyme linked immunosorbent assay (ELISA)
according to the protocols of the manufacturers. Plasma homo-
cysteine (Hcy) was determined by high-performance liquid chro-
matography and ﬂuorescence detection. Ultrasensitive CRP (hs-
CRP) was measured by nephelometry (Dade Behring, Marburg,
Germany). Total cholesterol, high-density lipoprotein (HDL) and
low-density lipoprotein (LDL) cholesterol as well as triglyceride
(TG) were measured with standard colourimetric methods (Roche
Diagnostics, Zug, Switzerland). Ionised calcium, phosphorus, and
creatinine were measured by standard methods.
25-OH vitamin D was measured in serum by a radio-
immunoassay (RIA) double antibody assay (DiaSorin, Saluggia,
Italy), which has an excellent agreement with high-performance
liquid chromatography. Plasma intact parathormone (iPTH) was
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assay (Access Intact PTH, Beckman Coulter, Inc., Fullerton, CA, USA).
Statistical analysis
Results are expressed as mean  standard deviation (SD). For
baseline variables, continuous variables were compared using an
independent t-test and categorical variables were compared using
the chi-square test. Variables before and 1 month after substitution
were compared using a paired t-test. Multiple linear regression
analysis was performedwhen looking for parameters inﬂuenced by
vitamin D concentration. Furthermore, one-way analysis of vari-
ance (ANOVA) was used to assess the relationship between quar-
tiles of vitamin D concentration at baseline and their respective
values of the measured parameters. Finally, a power analysis based
on the results of this study was done to look for the number of
patients to be included into a study to detect a change in
augmentation index. Statistic was performed with Statistical
Package for Social Sciences (SPSS) version 19.
Results
From a total of 76 consecutive patients with PAD, 65 (86%)
resulted vitamin D deﬁcient (25-OH vitamin D <30 ng ml1), with
20 patients (31%) showing a 25-OH vitamin D level <15 ng ml1.
Three patients did not give consent for the study, leaving
31 subjects to be included for each group (Fig. 1). Thirty-two
patients were included in June and August, the other 30 from
September to February. The baseline details are presented in
Tables 1e3. At baseline, no signiﬁcant differences were found in 25-
OH vitamin D and iPTH levels, haemodynamic parameters
including peripheral and central blood pressure, endothelialFig. 1. Flow dfunction (LDF variation after ischaemic challenge), parameters of
coagulation and inﬂammation, medications as well as cardiovas-
cular risk factors. At baseline, 25-OH vitamin D levels correlated
only with iPTH (r¼0.4, P¼ 0.001) and not with other parameters,
including calcium and phosphate.
Single, oral, vitamin D administration of 100 000 IU signiﬁcantly
increased 25-OH vitamin D levels compared with placebo by about
50% (þ8 vs. þ0.5 ng ml1, P < 0.001), but individual responses
greatly varied (Fig. 2). In nine patients (5 (17%) from the vitamin D
group and 4 (13%) from the placebo group), 25-OH vitamin D levels
were in the normal range (i.e., >30 ng ml1) after 1 month; all
patients were recruited during summer. In a multivariate regres-
sion model, serum 25-OH vitamin D concentration at 1 month was
related to its baseline level, to vitamin D substitution and to
seasonal factors, which accounted for a decrease of 8 ng/ml
between summer and winter, for an R2 of 0.55 in this model
(P < 0.0001).
Therewas no other signiﬁcant correlationwith 25-OH vitamin D
levels when dividing the parameters in quartiles (data not shown).
Metabolic parameters associated with vitamin D effects, surro-
gates of inﬂammation and haemostasis and haemodynamic
parameters did not change signiﬁcantly after vitamin D substitu-
tion between the two groups (Tables 4 and 5). However, there was
a trend for microcirculatory improvement after vitamin D supple-
mentation with a post-ischaemic increase of LDF from 13.5  16.8
to 20.6  16.0 AU (P ¼ 0.097) (difference of LDF ﬂux after ischaemic
challenge between groups: 8.0 AU, conﬁdence interval (CI): e1.1 to
17.2, P ¼ 0.06, Table 4). No side effects were observed during the
study in either group of patients. A calculation of the sample size
necessary to have an 80% power to detect a difference in the means
of the augmentation index yielded 253 subjects per group, for
a total sample size of about 500 patients.iagram.
Table 3
Baseline laboratory characteristics.
Control group
(n ¼ 31)
Vitamin D
supplementation
group (n ¼ 31)
P value
25-OH-vitamin D (ng/ml) 17.0  5.5 16.3  6.7 0.63
iPTH (pmol/L) 5.5  2.1 5.4  3.2 0.92
Calcium, ionized (mmol/L) 1.2  0.05 1.19  0.04 0.55
Phosphorus (mmol/L) 1.13  0.17 1.09  0.17 0.32
Creatinine (mmol/L) 79  23.7 82.5  22.1 0.56
LDL-cholesterol (mmol/L) 2.62  1.0 2.85  1.13 0.4
hs-CRP (mg/L) 3.7  5.2 2.7  2.8 0.35
Homocysteine,
total (mmol/L)
15.3  5.8 14.1  5.1 0.4
TAT (mg/L) 6.76  3.76 6.95  5.79 0.88
F1þ2 (pmol/L) 230  94.7 251  132.9 0.49
D-dimer (ng/ml) 0.81  0.51 1.0  1.25 0.44
PAI-1 (pg/ml) 663  431.1 653  552.0 0.93
sCD40L (ng/ml) 0.22  0.22 0.27  0.26 0.5
Baseline laboratory characteristics (mean  SD) in the control (n ¼ 31) and the
vitamin D supplementation group (n¼ 31). iPTH denotes intact parathormone; TAT,
thrombin antithrombin complex; F1þ2, prothrombin fragment 1 þ 2; PAI-1, plas-
minogen activator inhibitor-1.
Table 1
Baseline demographic characteristics.
Control group
(n ¼ 31)
Vitamin D
supplementation
group (n ¼ 31)
P value
Age (years) 74.8  14.6 72.9  8.7 0.5
Male sex (%) 19/31 (61) 19/31 (61) 0.94
Smoker
(yes/no/ex)
14/9/8 8/9/14
Diabetes
mellitus (%)
7 (23) 10 (32) 0.57
Hypertension (%) 23 (74) 24 (77) 0.77
Aspirin
/Clopidogrel (%)
31 (100) 31 (100) 1
Statins (%) 28 (90) 23 (74) 0.18
ACE-I/Sartane (%) 19 (61) 18 (53) 1
b-Blocker (%) 12 (39) 12 (39) 1
Ca-antagonist (%) 6 (19) 7 (23) 1
Insulin (%) 1 (3) 3 (10) 0.6
Oral
antidiabetics (%)
3 (10) 7 (23) 0.3
Baseline demographic characteristics (mean  SD) in the control (n ¼ 31) and the
vitamin D supplementation group (n ¼ 31).
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In observational studies, reviews and meta-analysis, vitamin D
deﬁciency was associated with cardiovascular outcomes and
mortality,6,11,16 venous thrombo-embolism,17 arterial stiffness and
vascular dysfunction14,18 as well as inﬂammatory parameters.19
However, observational studies might be subject to bias, and
randomised, controlled trials are felt to provide more reliable data
by reducing the possibility of confounding or selection bias.20
In this double-blinded, randomised, interventional pilot study
addressing elderly patients with PAD, a single, oral supplementa-
tion with 100 000 IU of vitamin D3 signiﬁcantly increased serum
vitamin concentration by 50%, interestingly without a decrease in
iPTH concentration. Although we used a high-dose supplementa-
tion, only 17% of the patients (5 of 31) reached the target concen-
tration of 30 ng ml1, and all of them were randomised during
summer.
The main objective of this study was to assess the impact of
vitamin D substitution on cardiovascular surrogate parameters.
Moreover, in the case of insigniﬁcant variations of these markers,
a power calculation based on our data would have permitted esti-
mating the number of patients to be included in future trials. Based
on a previous study, where endothelial function, measured by ﬂow-
mediated vasodilation, and blood pressure improved in 17 diabetic,
vitamin D-deﬁcient patients substituted with a single dose of
100 000 U of vitamin D2,21 we felt that the number of patientsTable 2
Baseline haemodynamic characteristics.
Control group
(n ¼ 31)
Vitamin D
supplementation
group (n ¼ 31)
P value
P-SBP (mmHg) 140  18.7 133  18.5 0.16
P-DBP (mmHg) 76  8.0 73  8.2 0.17
Heart rate (bpm) 65  10 67  11 0.38
C-SBP (mmHg) 132  17.1 124  17.1 0.11
C-DBP (mmHg) 77  8.0 74  8.3 0.18
AIx (%) 39.5  7.1 38.6  7.3 0.77
D LDF (AU) 15.2  14.0 13.5  16.8 0.66
Baseline haemodynamic characteristics (mean  SD) in the control (n ¼ 31) and the
vitamin D supplementation group (n ¼ 31). P-SBP denotes peripheral systolic blood
pressure; P-DBP, peripheral diastolic blood pressure; C-SBP, central (aortic) systolic
blood pressure; C-DBP, central diastolic blood pressure; AIx, aortic augmentation
index; D LDF, postischemic increase of laser Doppler ﬂux.included in this study would have been adequate. AIx, among other
parameters, is considered to be a complex and composite marker of
arterial stiffening; furthermore, endothelial dysfunction and arte-
rial stiffness have been shown to precede and contribute to the
development of cardiovascular disease.14 AIx measurement is less
operator-dependent compared to the assessment of endothelial
function and has shown excellent inverse correlation with vitamin
D concentration,14 which prompted us to use AIx for power calcu-
lation. Based on these premises and on our data, we could not
demonstrate a decrease of central and peripheral blood pressure by
vitamin D supplementation, nor could we show an improvement in
arterial stiffness and in endothelial function, with unchanged
values for AIx and difference in LDF, respectively. We feel that the
necessity for a study with a surrogate marker to include >500
subjects, as resulted from our data, may point to a potentially low
impact of vitamin D substitution on clinical outcomes.
A second objective of our study was to assess the impact of
a vitamin D supplementation on coagulation and inﬂammation, by
measuring TAT and F1þ2 (markers for thrombin generation),
D-dimer and PAI-1 (markers for ﬁbrinolysis), sCD40L (marker for
platelet activation), hsCRP (marker for inﬂammation) and Hcy. WeFig. 2. Individual serum levels of 25-OH vitamin D ad baseline and 1 month after
supplementation with 100 000 IU of oral vitamin D3.
Table 4
Blood pressure, aortic stiffness and endothelial function before and after
supplementation.
Control group Vitamin D group
Baseline After 1
month
P value Baseline After 1
month
P value
P-SBP
(mmHg)
140  18.7 143  18.2 0.27 133  18.5 136  18.7 0.24
P-DBP
(mmHg)
76  8.0 76  10.1 1 73  8.2 73  8.1 0.74
C-SBP
(mmHg)
132  17.1 134  17.8 0.28 124  17.1 127  18.0 0.37
C-DBP
(mmHg)
77  8.0 77  10.3 0.99 74  8.3 74  8.3 0.61
AIx (%) 39.5  7.1 38.6  7.2 0.65 38.6  7.3 38.5  8.7 0.93
D LDF (AU) 15.2  14.0 14.3  10.8 0.77 13.5  16.8 20.6  16.0* 0.097
Haemodynamic parameters at baseline and 1 month after supplementation with
100 000 IU of oral vitamin D3 or placebo. P-SBP denotes peripheral systolic blood
pressure; P-DBP, peripheral diastolic blood pressure; C-SBP, central (aortic) systolic
blood pressure; C-DBP, central diastolic blood pressure; AIx, aortic augmentation
index; D LDF, postischemic increase of laser Doppler ﬂux.
*P value ¼ 0.06 for difference between groups.
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We are aware of only one study where the inﬂuence of vitamin D
supplementation on parameters of thrombosis was analysed; no
change of plasma levels of PAI-1, tPA Ag and thrombin generation
was observed.22
These ﬁndings are in contrast with previous studies.21,23 In
a similar study, Pfeifer et al. demonstrated a 9% decrease in systolic
blood pressure 6 weeks after giving vitamin D supplements to
severely vitamin-D-deﬁcient women whose serum vitamin level
increased to 26 ng ml1.23
Other studies, however, support our results. In a randomised,
controlled interventional trial, a 4-monthly oral 100 000 IU
vitamin D3 substitution during 5 years in subjects more than 65
years old had no effect on total or cardiovascular mortality but
prevented fractures.24 In the RECORD (Rosiglitazone Evaluated for
Cardiac Outcomes and Regulation of Glycaemia in Diabetes) trial,
5292 patients aged at least 70 years with osteoporotic fractures
were randomised to 800 IU vitamin D3 daily, 100 mg of calcium,
both, or placebo. No effect on mortality or vascular disease was
detected after a 3 years’ follow-up.25 In a recent systematic review
and meta-analysis of 51 randomised interventional trials, Elamin
et al. did not ﬁnd a signiﬁcant effect of vitamin D supplementation
on death, stroke, myocardial infarction, lipids and blood
pressure.26
Our negative result deserves some comments. First, our patients
were well treated for their cardiovascular risk factors with 82% of
the whole population taking statins and a majority of the hyper-
tensive patients treated with angiotensin-converting enzyme (ACE)
inhibitors, sartanes or calcium antagonists, which may have left noTable 5
Coagulation and inﬂammation parameters before and after supplementation.
Control group
Baseline After 1 month P
TAT (mg/L) 6.76  3.76 9.0  6.2 0
F1þ2 (pmol/L) 230  94.7 229  100.4 0
D-Dimer (ng/ml) 0.81  0.51 0.81  0.45 0
PAI-1 (pg/ml) 663  431.1 630  408.5 0
sCD40L (ng/ml) 0.22  0.22 0.2  0.19 0
Hcy (mmol/L) 15.3  5.2 15.7  5.7 0
hsCRP (mg/L) 3.7  5.2 2.8  2.8 0
Coagulation and inﬂammation parameters at baseline and 1 month after supplementation
complex; F1þ2, prothrombin fragment 1 þ 2; PAI-1, plasminogen activator inhibitor-1;space for further improvements of surrogate parameters. Second,
established and widespread cardiovascular disease could have led
to irreversible alterations of the vascular wall, which could have
hampered a positive response to develop. Third, the short follow-
up period could have blunted a possible response, but a longer
observation period would have raised concerns about confounding
factors such as sun exposure, and previous studies found a reducing
effect on blood pressure by vitamin D substitution after a similar
period of time.21 Taken together, our ﬁndings do not support the
hypothesis that vitamin D substitution has a decisive effect on
cardiovascular risk factors, although the study was underpowered
to deﬁnitively exclude such an inﬂuence.
In this study, a single, oral dose of 25-OH cholecalciferol
increased serum vitamin D levels by 50%, and seasonal factors
accounted for a decrease of about 8 ng/ml between summer and
winter, which may cause a 30e50% variation in individual serum
vitamin levels throughout a year. Vitamin D deﬁciency was
frequently observed in our patients suffering from PAD, with 86%
of serum levels below 30 ng/ml. Interestingly, individual
responses to supplementation greatly varied (Fig. 2). The factors
known to inﬂuence vitamin D levels in healthy subjects include
age, body weight, race, sun exposure and probably also genetic
factors.27
There are several strengths in our study. In this well-deﬁned
subset of cardiovascular patients with PAD, we did an interven-
tional study with a single, oral dose of vitamin D, which
circumvents problems with patient adherence regularly found in
long-term studies. Although a single dose often fails to attain
a desired serum 25-OH vitamin D concentration,28 even in longer-
range studies serum levels did not increase bymore than 40%.24We
acknowledge, however, that a concentration-driven supplementa-
tion of vitamin D, by obtaining serum levels above a pre-speciﬁed
threshold, would have resulted in a more irreprehensible inter-
pretation of our data.
Seasonal inﬂuences on sun exposure of the patients is a weak-
ness in this trial and could have diluted our results, but the absence
largely found of an association between vitamin D levels and
cardiovascular surrogate parameters make this a very remote
hypothesis.
In summary, although a single, high-dose oral supplementa-
tion with 25-OH cholecalciferol increased serum vitamin levels
by 50% after 1 month, there was no change in cardiovascular
surrogate parameters in vitamin D-deﬁcient patients with PAD.
Individual response of serum concentrations greatly varied. A
sufﬁciently powered study is needed to deﬁnitely exclude an
inﬂuence of vitamin D on cardiovascular surrogate parameters
such as arterial stiffness. The ﬁnal answer whether substitution of
vitamin D has an impact on cardiovascular disease must attend
the results of the eagerly awaited ongoing large-scale interven-
tional trials.Vitamin D group
value Baseline After 1 month P value
.1 6.95  5.8 7.1  3.5 0.94
.97 251  132.9 277  191.6 0.54
.97 1.0  1.25 0.89  1.22 0.94
.76 653  552.0 567  341.7 0.47
.68 0.27  0.26 0.3  0.28 0.66
.71 14.2  5.1 13.8  4.8 0.64
.42 2.7  2.8 3.0  2.3 0.61
with 100 000 IU of oral vitamin D3 or placebo. TAT denotes thrombin antithrombin
Hcy, total homocysteine.
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